ANDA 217626, held by Stira. Cupric Chloride.
As of Nov 16, 2026, ANDA 217626 (Cupric Chloride), held by Stira, was first approved by FDA on Apr 30, 2024, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Cupric chloride injection, USP is indicated for use as a supplement to intravenous solutions given for TPN. Administration helps to maintain copper serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 30, 2024 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Cupric ChlorideEQ 0.4MG COPPER/ML · injectable;injection | Cupric Chloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters